A：Since the last quarter, clinical reviews have increased by more than 50%.

A：New self-service digital scheduling tools, including AI-enabled tools, have improved access, reduced friction, and expanded capacity without adding incremental clinical burden.

A：Optum Financial Services is performing well and has agreed to acquire Lead Technologies, a leading health financial services business, to provide more flexible consumer-centered solutions.

A：In the first quarter, adjusted earnings per share was $7.23, well ahead of expectations, backed by strong quality metrics and supported by solid operating cash flows and reserves.

A：Total revenues were $111.7 billion, reflecting 2% growth year over year, driven by disciplined pricing actions and member mix. The medical care ratio was 83.9%, reflecting strong medical cost management and favorable reserve development.

A：The operating cost ratio was 84.4%, reflecting targeted investments and incentive compensation of $900 million for the quarter, which is expected to normalize as these investments scale and deliver productivity benefits.

A：The company's capital priorities are to invest in growth, strengthen the balance sheet, and return value to shareholders. This quarter, they brought down the debt to capital ratio and initiated share repurchases, expecting to deploy at least $5 billion by the end of the second quarter.

A：Earnings are weighted more heavily in the first half of the year, with a significant majority of full year reported earnings occurring in the first half. The full year outlook has been updated to greater than $20 a share, which balances first quarter performance with a prudent level of patience.

A：Earnings are over 75% weighted to the first half of the year for UnitedHealthcare, and for Optum Health, earnings are expected to moderate throughout the year with most occurring in the first half. In contrast, Optum Insight and OptumRx are more weighted to the back half, generating approximately 50% of earnings in the second half.

A：The general consensus is that the Medicare Advantage cost trend is running about 7-8%, with the company's expectations being consistent with historical trends and a focus on pricing around 10% for 2026.

A：The current sentiment toward government programs is modestly favorable, but it is progressing at elevated high levels. An inflection point is not yet evident, and the company remains comfortable with its pricing posture for 2026 based on early results.

A：The exact size of the trend component attributed to acuity dynamics is not specified, but the company has taken several actions to address it, such as improving product positioning in Medicare Advantage, enhancing tools for early identification of outlier patterns, and engaging in clinical programs, payment integrity programs, and network actions.

A：The first quarter's performance in Optum Health was driven by two main factors: the restatement of medical expenses from prior periods favorably relative to expectations, particularly in markets where the company has focused on clinical and medical management efforts; and a 12% year-over-year increase in patient facing hours due to improved operating performance and cost management. These improvements are expected to continue and are being scaled across all markets.

A：For the comparison of adjusted earnings for the first quarter to the guidance, one should compare the 1.3 billion reported to the adjusted guidance of 1.575 billion provided originally for the true run rate. This comparison removes noncash accounting implications of the lost contract and the final disposition of assets in the quarter.

A：Internal expectations for adjusted earnings were not explicitly stated, but the results exceeded these expectations as all four segments did better than anticipated. Specific actions taken in the fourth quarter contributed to this favorable performance.

A：The plan for the balance program involves an active dialogue with CMS and CMI. The goal is to find a path to sustainable coverage, but there are challenges with the current structure that need to be addressed internally. The company looks forward to continued dialogue and will provide recommendations to serve all stakeholders. Participation in the bridge demonstration starting in July is anticipated to yield further insights.

A：The outlook for margin recovery in 2027 is focused on financial sustainability and product durability, aiming for the upper half of the 2 to 4% long-term range previously discussed. The company is exploring the balance program and is part of the bridge demonstration, learning about the best ways to advance this priority through experience. While the company has engaged in the balance program, participation in the balance program is not expected to meet industry thresholds.

A：The strategy involves slowly decommissioning old products that were not AI-based and reinvesting in those products through AI investments. This will result in the slow rundown of the old products and their transition to more AI-based ones, with the benefits expected to be realized in the back half.

A：The company is onboarding almost 1,000 new clients this year, the majority of which will be in the run rate next year. This will result in a reduced impact of new client onboarding as the year progresses, with benefits from GNA initiatives and AI investments becoming apparent in the back half.

A：The PBM business is impacted by legislation, particularly in Tennessee, which is of concern due to its implications for access to specialty and behavioral health pharmacies. This will harm access for approximately 150,000 Tennesseans with complex conditions. The company is advocating for those affected and monitoring the impact of legislation beyond Tennessee.

A：The company has put itself in a leadership position in the industry with regard to independent pharmacy stability, ensuring that 100% of independent pharmacies are reimbursed with a cost-based mechanism. It's also expanding health system pharmacies and providing affordability to members through various initiatives like Price Edge and critical drug affordability programs, delivering over $1.5 billion in affordability this year.

A：The advancements include the growth of Precheck by Prior off, which is being scaled with Cleveland Clinic to serve over 20 health systems and ongoing work to streamline prior authorizations for 180 drugs. The company is also focusing on pay transparency, which is driving growth and is reflected in the strong selling season.

A：The PDR for the full year is estimated to be north of $600 million, with the team actively negotiating to renegotiate contracts to appropriate rates or to deleverage or exit. Q1 numbers are expected to be slightly lower due to some disposed assets with a PDR associated with them. Negotiations are ongoing, and the company is confident in reaching settlements for 2027.

A：The company is investing $1.5 billion in AI across United Health Group, with a third dedicated to software products and platform acceleration, and the rest in end-to-end processes and functions. This investment is expected to result in a return of 2 to 1 on programs over the next few years, with many paying back within 12 to 18 months. Some of the AI-first products are seeing external traction, and the company is aligning its efforts to achieve structural growth rate shifts in revenue, while being measured in terms of expectations due to the novelty of the investment.

A：The strategy for deploying modernization across the enterprise involves targeting large core processes with an aim to modernize them, ultimately taking these modernized functions to the outside marketplace and large overall functions. The potential impact is significant, but it's considered premature to predict the specific impact at this stage, as the company is strategically investing to maintain competitiveness and provide long-term positive effects for consumers and the experience with the organization.

A：The company originally provided guidance of approximately $2.5 billion in back-half loaded capital deployment, mainly focusing on productivity increases. Although the intrinsic value discount led the company to decide to accelerate some investments, there were no changes in the guidance. This is to ensure shareholders receive the benefits sooner, driven by the confidence in the company's results. The process is expected to return to previous levels, indicating a restoration of the original program.

A：The impact of the PYD in the quarter, which amounted to a net amount of around $500 million, is difficult to allocate precisely between the UHC (United Health Care) impact and the Oh impact. The company believes that the established level of conservatism will become more evident as developments from Q1 continue to unfold in April and May. At this stage, the company advises patience due to the novelty of the quarter.

A：The company remains supportive of the policy to advance the Medicare Advantage program and improve health outcomes. However, the implementation of the proposed model recalibration, which is now delayed, concerns the company due to its potential impact on patients with chronic conditions. While the company cannot predict the exact impact once the model is implemented, it believes in the value of its polyconic patient approach and the effectiveness of its value-based care model. Improvements to the program and the commitment to value-based care indicate a strong alignment with CMS's goals.

A：The contribution to the United Health Foundation is directly linked to the gains from the sale and closure of the company's European operations. The gains, amounting to more than $500 million, were realized within Optum Insight and the entirety of this gain was allocated to the foundation. This approach of using foundation contributions to advance the healthcare system is a pattern the company plans to continue, reflecting its commitment to the healthcare system and the responsibility it bears in that regard.

A：The company is appreciative of the ongoing engagement with CMS and the opportunities for program modernization. While the company does not speculate on potential changes to the program in future years, it does support efforts to improve the program, such as the finalization of chart linking in the latest rule. The company is committed to simplifying and modernizing the system, viewing value-based care as a critical tool for long-term success. The company is prepared to partner with CMS on any efforts that ensure program stability and appropriate testing.

A：The company is achieving modest outperformance across various cost categories within government programs under the umbrella of UHC. Although it's still early to provide detailed specificity on utilization patterns, the performance is generally aligned with expectations and is across the board based on the visibility available at this point in the first quarter. The company focuses on managing drug costs and aims to save billions through affordability. Additionally, Optum Health programs are designed to decrease hospital admissions and provide better, more affordable care, which contributes to cost savings across the care continuum.